Wai L. Lau
About Wai L. Lau
Wai L. Lau is a Senior Research Investigator II at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in biophysics, biochemistry, and business administration.
Company
Wai L. Lau is currently employed at Bristol Myers Squibb as a Senior Research Investigator II. This position is located in Cambridge, Massachusetts, United States.
Previous Experience at Adnexus
Wai L. Lau previously worked at Adnexus, a Bristol-Myers Squibb R&D Company, as a Staff Scientist. He held this position from 2010 to 2013, spending three years contributing to the company's research efforts in the Greater Boston Area.
Education and Advanced Studies
Wai L. Lau has an extensive academic background. He completed a Master of Business Administration (MBA) at Carnegie Mellon University's Tepper School of Business from 2007 to 2009. He achieved his PhD in Biophysics from the University of Pennsylvania School of Medicine, spanning eight years from 1995 to 2003. Prior to that, he earned a Bachelor of Science (BS) degree in Chemistry from the University of Oregon, studying from 1992 to 1995.
Research and Technical Contributions
Wai L. Lau has made significant contributions in the field of biotechnology. He pioneered an antibody Fab-fragment selection system using yeast surface display and yeast mating and validated the SECANT yeast display technology for selecting full-length IgG and Adnectins. He adapted yeast display methods for selecting Fab and Adnectin libraries against membrane proteins. Furthermore, he re-engineered two kinases to improve their expression and biophysical properties, facilitating crystallization and crystal structure determination. Additionally, he extended these methodologies to engineer five more challenging target proteins.
Technical Leadership and Collaborations
As the technical lead for the departmental BD FACS ARIA II and ARIA III cell sorters, Wai L. Lau provided essential technical support to users and collaborated with BD engineers. He designed and constructed Flp-In plasmids for surface display of full-length IgG and other proteins. Furthermore, he completed the affinity maturation of Adnectin leads for PET imaging of three immuno-oncology markers.